Companies Adma Biologics, Inc
Adma Biologics (ADMA): executive pay, fiscal 2025
Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Adma Biologics, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask, and a copy by email. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
CEO vs. named peers57th pct.Of 21 peer CEOs
CEO pay, last three years
- $6,039,649FY2023
- $7,918,734FY2024
- $10,237,326FY2025
CEO total pay was $10,237,326 in fiscal 2025, up from $7,918,734 in fiscal 2024.
FY2025: salary $925,000 · bonus $0 · stock awards $4,049,994 · option awards $4,049,998
Executives and directors
Frequently asked questions
Who was the highest-paid executive at Adma Biologics, Inc in fiscal 2025?
As disclosed, Adam Grossman (President, Chief Executive Officer and Director) was the highest-paid executive at Adma Biologics, Inc in fiscal 2025, with total compensation of $10,237,326.
How does Adma Biologics, Inc's chief executive pay compare to its disclosed peer group?
As disclosed, Adam Grossman's total compensation ranked at the 57th percentile of Adma Biologics, Inc's disclosed peer group.
What is Adma Biologics, Inc's CEO-to-median employee pay ratio?
As disclosed, Adma Biologics, Inc's CEO-to-median employee pay ratio was 120:1.
How did shareholders vote on Adma Biologics, Inc's executive compensation?
As disclosed, 95.43% of shareholders supported Adma Biologics, Inc's executive compensation in the latest say-on-pay vote.
How much does Adma Biologics, Inc spend in total on board compensation for fiscal 2025?
As disclosed, Adma Biologics, Inc reported total board compensation of $1,544,916 for fiscal 2025.
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Adam Grossman | $925,000 | $0 | $4,049,994 | $4,049,998 | $1,156,250 | $0 | $56,084 | $10,237,326 |
| President, Chief Executive Officer and Director | ||||||||
| Kaitlin Kestenberg | 575,000 | 0 | 1,249,989 | 1,249,999 | 359,375 | 0 | 54,284 | 3,488,647 |
| Chief Operating Officer & Senior Vice President, Compliance | ||||||||
| Brad Tade | 500,000 | 0 | 999,988 | 999,997 | 250,000 | 0 | 73,645 | 2,823,630 |
| Former Executive Vice President and Chief Financial Officer | ||||||||
| Paul Kohler | 19,231 | 0 | 1,124,988 | 1,124,988 | 15,750 | 0 | 11,992 | 2,296,949 |
| Current Chief Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Adam Grossman | $10,237,326 | $7,918,734 | $6,039,649 | ↑ +2,318,592 |
| Kaitlin Kestenberg | 3,488,647 | 3,340,020 | — | ↑ +148,627 |
| Brad Tade | 2,823,630 | 2,936,435 | — | ↓ −112,805 |
| Paul Kohler | 2,296,949 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Compensation Committee designs compensation programs to align executive compensation with corporate strategies and business objectives, subject a substantial portion of compensation to achieving short-term and long-term performance objectives, and provide total direct compensation that is competitive in the marketplace.
| CEO STI target (% of salary) | 100% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | Pay Governance LLC |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | — |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Paul Kohler | OPTION | 2025-12-08 | — | — | 91,166 | — | $2,250,000 |
| Adam S. Grossman | OPTION | 2025-02-19 | — | — | 376,744 | — | 8,100,000 |
| Brad Tade | OPTION | 2025-02-19 | — | — | 93,023 | — | 2,000,000 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Paul Kohler | $0 | $0 | $2,250,000 | 0.0% |
| Adam S. Grossman | 0 | 0 | 8,100,000 | 0.0% |
| Brad Tade | 0 | 0 | 2,000,000 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Kaitlin Kestenberg | RSU | 10,000 | — | $182,400 |
| Kaitlin Kestenberg | RSU | 15,000 | — | 273,600 |
| Brad Tade | RSU | 37,500 | — | 684,000 |
| Grossman | Option | 37,500 | 1.67 | — |
| Kaitlin Kestenberg | RSU | 47,500 | — | 866,400 |
| Brad Tade | RSU | 50,000 | — | 912,000 |
| Brad Tade | RSU | 54,300 | — | 990,432 |
| Paul Kohler | RSU | 58,019 | — | 1,058,267 |
| Brad Tade | RSU | 62,227 | — | 1,135,020 |
| Brad Tade | Option | 74,336 | 13.58 | — |
| Grossman | RSU | 75,000 | — | 1,368,000 |
| Kaitlin Kestenberg | RSU | 77,784 | — | 1,418,780 |
| Paul Kohler | Option | 91,166 | 19.39 | — |
| Brad Tade | Option | 93,023 | 16.07 | — |
| Kaitlin Kestenberg | Option | 116,479 | 16.07 | — |
| Kaitlin Kestenberg | RSU | 144,240 | — | 2,630,938 |
| Kaitlin Kestenberg | Option | 175,192 | 6.54 | — |
| Grossman | RSU | 252,022 | — | 4,596,881 |
| Grossman | RSU | 286,848 | — | 5,232,108 |
| Grossman | Option | 358,558 | 3.35 | — |
| Grossman | Option | 376,744 | 16.07 | — |
| Grossman | RSU | 418,296 | — | 7,629,719 |
| Grossman | Option | 471,765 | 5.4 | — |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Steven A. ElmsIndependent · Nominating/Governance | $96,250 | $174,986 | $174,999 | $0 | $0 | $446,235 |
| Young T. KwonIndependent · Compensation (Chair) · Audit (Chair) | 95,000 | 174,986 | 174,999 | 0 | 0 | 444,985 |
| Jerrold B. GrossmanNot independent | 90,000 | 174,986 | 174,999 | 0 | 0 | 439,985 |
| Lawrence P. GuiheenIndependent · Compensation · Nominating/Governance (Chair) · Audit | 85,000 | 174,986 | 174,999 | 0 | 0 | 434,985 |
| Alison C. FingerIndependent · Compensation · Nominating/Governance | 66,250 | 174,986 | 174,999 | 0 | 0 | 416,235 |
| Eduardo Rene SalasIndependent · Audit | 62,500 | 174,986 | 174,999 | — | — | 412,485 |
| Adam S. GrossmanEmployee director | — | — | — | — | — | 0 |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | $174,986 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 25,000 / 20,000 / 12,500 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $495,000 |
| Equity awards (grant-date value) | $1,049,916 |
| All other compensation | $0 |
| Total cost of the board | $1,544,916 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Adma Biologics as a peer
Companies that benchmark against ADMA
8 companies name ADMA as a compensation peer
- ARDELYX, INC.ARDXFY2025
- BIOCRYST PHARMACEUTICALS INCBCRXFY2025
- IRONWOOD PHARMACEUTICALS INCIRWDFY2024
- MANNKIND CORPMNKDFY2025
- MIMEDX GROUP, INC.MDXGFY2025
- RxSight, Inc.RXSTFY2025
- TG THERAPEUTICS, INC.TGTXFY2025
- Xeris Biopharma Holdings, Inc.XERSFY2025
Each company listed discloses ADMA in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named ADMA in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
Disclosed peer group — fiscal year 2025
The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.
APLS Apellis Pharmaceuticals, Inc.CPRX Catalyst Pharmaceuticals, Inc.FOLD Amicus Therapeutics, Inc.ITCI Intra-Cellular Therapies, Inc.TGTX TG Therapeutics, Inc.AMPH Amphastar Pharmaceuticals, Inc.ANIP ANI Pharmaceuticals, Inc.EOLS Evolus, Inc.MDXG MiMedx Group, Inc.MIRM Mirum Pharmaceuticals, Inc.SRPT Sarepta Therapeutics, Inc.SUPN Supernus Pharmaceuticals, Inc.ALKS Alkermes plcCORT Corcept Therapeutics IncorporatedVCEL Vericel CorporationEXEL Exelixis, Inc.ACAD ACADIA Pharmaceuticals Inc.HRMY Harmony Biosciences Holdings, Inc.COLL Collegium Pharmaceutical, Inc.HALO Halozyme Therapeutics, Inc.MNKD MannKind Corporation
Peer reciprocity
The companies Adma Biologics, Inc names as compensation peers that name it back in their own disclosed peer groups.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Exelixis, Inc. | 2025 | Michael Morrissey | $1,306,040 | $30,539,552 | $0 | $1,382,591 | $33,239,183 |
| 2 | TG Therapeutics, Inc. | 2025 | Michael Weiss | 875,000 | 23,550,000 | 0 | 1,146,250 | 25,571,250 |
| 3 | Halozyme Therapeutics, Inc. | 2025 | Helen Torley | 1,000,000 | 19,350,145 | 1,650,014 | 1,147,500 | 23,166,223 |
| 4 | Supernus Pharmaceuticals, Inc. | 2025 | Jack Khattar | 1,036,000 | 6,535,029 | 7,031,545 | 846,930 | 15,501,557 |
| 5 | Corcept Therapeutics Incorporated | 2025 | Joseph Belanoff | 1,182,333 | 0 | 12,907,718 | 0 | 15,303,551 |
| 6 | Vericel Corporation | 2025 | Dominick Colangelo | 860,000 | 3,964,630 | 5,456,287 | 860,000 | 11,156,368 |
| 7 | Apellis Pharmaceuticals, Inc. | 2024 | Cedric Francois | 793,193 | 4,779,832 | 4,787,768 | 0 | 10,957,451 |
| 8 | Mirum Pharmaceuticals, Inc. | 2025 | Christopher Peetz | 755,000 | 3,683,904 | 4,931,320 | 1,057,000 | 10,441,224 |
| 9 | ANI Pharmaceuticals, Inc. | 2025 | Nikhil Lalwani | 837,409 | 7,848,711 | 0 | 1,572,500 | 10,278,620 |
| 10 | Adma Biologics, Inc | 2025 | Adam Grossman | 925,000 | 4,049,994 | 4,049,998 | 1,156,250 | 10,237,326 |
| 11 | Intra-Cellular Therapies, Inc. | 2023 | Sharon Mates | 891,653 | 7,749,984 | 0 | 0 | 10,086,413 |
| 12 | MannKind Corporation | 2025 | Michael Castagna | 789,436 | 7,689,480 | 0 | 675,757 | 9,300,485 |
| 13 | Amicus Therapeutics, Inc. | 2024 | Bradley Campbell | 767,308 | 4,990,365 | 2,105,627 | 0 | 8,526,943 |
| 14 | Amphastar Pharmaceuticals, Inc. | 2025 | Jack Yongfeng Zhang | 950,911 | 3,301,981 | 3,302,024 | 361,000 | 8,309,350 |
| 15 | Acadia Pharmaceuticals Inc. | 2025 | Catherine Owen Adams | 930,000 | 3,240,558 | 3,234,797 | 818,559 | 8,256,518 |
| 16 | Alkermes plc | 2025 | Richard Pops | 1,250,769 | 0 | 5,020,812 | 1,626,000 | 7,915,081 |
| 17 | Harmony Biosciences Holdings, Inc. | 2025 | Jeffrey Dayno | 743,600 | 1,976,520 | 4,599,000 | 558,000 | 7,899,535 |
| 18 | Sarepta Therapeutics, Inc. | 2025 | Douglas Ingram | 1,171,425 | 6,000,005 | 0 | 649,000 | 7,840,666 |
| 19 | Catalyst Pharmaceuticals, Inc. | 2024 | Richard Daly | 750,000 | 1,267,601 | 5,070,830 | 0 | 7,774,160 |
| 20 | MiMedx Group, Inc. | 2025 | Joseph Capper | 768,173 | 4,699,000 | 819,422 | 887,800 | 7,182,208 |
| 21 | Evolus, Inc. | 2025 | David Moatazedi | 775,000 | 3,886,569 | 1,296,697 | 429,000 | 6,412,214 |
| 22 | Collegium Pharmaceutical, Inc. | 2025 | Vikram Karnani | 875,000 | 0 | 0 | 835,406 | 1,715,846 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Incentive design against the same peers
| Company | Annual incentive payout | Long-term vehicle mix | PSU measures include TSR | Compensation consultant |
|---|---|---|---|---|
| Adma Biologics, Inc | 125% | RSU 50 · Options 50 | not disclosed | Pay Governance LLC |
| Acadia Pharmaceuticals Inc. | 110% | Options 50 · PSU 25 · RSU 25 | Yes | Frederic W. Cook & Co., Inc. (FW Cook) |
| Alkermes plc | 130% | PRSU 53 · RSU 24 · Option 23 | Yes — Relative Total Shareholder Return (TSR) | Alpine Rewards LLC |
| Amicus Therapeutics, Inc. | not disclosed | Option 33 · RSU 33 · PRSU 33 | Yes — TSR Goal | Pay Governance |
| Amphastar Pharmaceuticals, Inc. | not disclosed | Options 50 · RSU 50 | not disclosed | Willis Towers Watson (WTW) |
| ANI Pharmaceuticals, Inc. | 185% | RSU 75 · PSU 25 | Yes — relative TSR against the constituents of the S&P 600 Pharmaceuticals, Biotechnology and Life Sciences Index | Pearl Meyer & Partners, LLC |
| Apellis Pharmaceuticals, Inc. | 90.74% | RSU 50 · PSU 50 | not disclosed | Pay Governance |
| Catalyst Pharmaceuticals, Inc. | not disclosed | not disclosed | not disclosed | Mercer LLC |
| Collegium Pharmaceutical, Inc. | 127.3% | RSU 70 · PSU 30 | Yes — relative ranking of the total shareholder return (TSR) of the Company's common stock in 2025, 2026, 2027 and the cumulative three-year performance period (2025-2027) return relative to the TSR of peer companies within the S&P Pharmaceutical Select Industry Index | Alpine Rewards, LLC |
| Corcept Therapeutics Incorporated | Dr. Belanoff: 100%; Dr. Guyer: 120%; Mr. Maduck: 80%; Mr. Mokari: 100%; Mr. Robb: 100%% | Stock Options 100 | not disclosed | not disclosed |
| Evolus, Inc. | 55% | not disclosed | No | Radford, an Aon Company |
| Exelixis, Inc. | 105% | PSU 50 · RSU 50 | Yes — 2025 Relative TSR Goal | Aon |
| Halozyme Therapeutics, Inc. | 127.5% | PSU 50 · RSU 35 · Option 15 | No | F.W. Cook & Co., Inc. |
| Harmony Biosciences Holdings, Inc. | 100% | not disclosed | not disclosed | Pay Governance |
| Intra-Cellular Therapies, Inc. | not disclosed | RSU 75 · PRSU 25 | Yes — Total Stockholder Return (TSR) of Company stock relative to the TSR of companies in the Nasdaq Biotechnology Index | Aon Consulting, Inc. |
| MannKind Corporation | 107% | PSU 55 · RSU 45 | Yes — Total Stockholder Return (TSR) relative to Russell 3000 Pharmaceutical & Biotechnology Index | Mercer LLC |
| MiMedx Group, Inc. | 115% | not disclosed | No | Willis Towers Watson |
| Mirum Pharmaceuticals, Inc. | 200% | Option 47.2 · PSU 17.6 · RSU 17.6 | No | Alpine Rewards |
| Sarepta Therapeutics, Inc. | 100% | PSU 50 · Option 25 · RSU 25 | No | FW Cook |
| Supernus Pharmaceuticals, Inc. | not disclosed | not disclosed | No | Aon |
| TG Therapeutics, Inc. | 131% | RSU 100 | No | Compensia, Inc. |
| Vericel Corporation | 100% | Options 58 · RSU 42 | not disclosed | FW Cook |
Read from each company’s Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company’s filing does not state the item.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2026 | 2026-06-02 | 168,169,866 | 7,730,690 | 326,116 | 95.43% | Passed |
| 2025 | 2025-06-04 | 161,456,980 | 19,869,072 | 266,852 | 88.91% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2026 | 2026-06-02 | 95.43%a |
| 2025 | 2025-06-04 | 88.91%b |
a. Approved under the standard stated in the filing — “Abstentions for this proposal will be counted as a vote AGAINST such proposal.”.
b. Approved under the standard stated in the filing — “Abstentions for this proposal will be counted as a vote AGAINST such proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
CEO pay ratio
| Ratio (CEO : median employee) | 120 : 1 |
|---|---|
| CEO total compensation | $10,237,326 |
| Median employee compensation | $85,586 |
Insider trades since the proxy
Every insider equity transaction reported on Form 4 after the 2025 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Jerrold B. Grossman | Director | 2026-05-11 | A | 12,500 | $8 | $100,125 | Common | Form 4 ↗ |
| Jerrold B. Grossman | Director | 2026-05-12 | A | 12,500 | 8 | 100,125 | Common | Form 4 ↗ |
| Jerrold B. Grossman | Director | 2026-05-27 | A | 6,400 | 8 | 50,624 | Common | Form 4 ↗ |
| Paul Kohler | CFO and Treasurer | 2026-07-16 | A | 85,130 | 0 | 0 | Common | Form 4 ↗ |
| Paul Kohler | CFO and Treasurer | 2026-07-16 | A | 136,363 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Kaitlin M. Kestenberg-Messina | COO and SVP, Compliance | 2026-07-24 | D | 3,177 | 8 | 26,591 | Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
Sources (51 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Adam Grossman. DEF 14A, filed 2026-04-15. Section “Executive Compensation”. As printed: 10,237,326. View filing ↗
- Section 01, Kaitlin Kestenberg. DEF 14A, filed 2026-04-15. Section “Executive Compensation”. As printed: 3,488,647. View filing ↗
- Section 01, Brad Tade. DEF 14A, filed 2026-04-15. Section “Executive Compensation”. As printed: 2,823,630. View filing ↗
- Section 01, Paul Kohler. DEF 14A, filed 2026-04-15. Section “Executive Compensation”. As printed: 2,296,949. View filing ↗
- Section 03, Paul Kohler OPTION. DEF 14A, filed 2026-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Adam S. Grossman OPTION. DEF 14A, filed 2026-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 03, Brad Tade OPTION. DEF 14A, filed 2026-04-15. Section “Grants of Plan-Based Awards” · grants of plan-based awards table. View filing ↗
- Section 07, pay ratio. DEF 14A, filed 2026-04-15. Section “CEO Pay Ratio”. As printed: 120 : 1. View filing ↗
- Section 08, Steven A. Elms. DEF 14A, filed 2026-04-15. Section “Director Compensation”. As printed: 446,235. View filing ↗
- Section 08, Young T. Kwon. DEF 14A, filed 2026-04-15. Section “Director Compensation”. As printed: 444,985. View filing ↗
- Section 08, Jerrold B. Grossman. DEF 14A, filed 2026-04-15. Section “Director Compensation”. As printed: 439,985. View filing ↗
- Section 08, Lawrence P. Guiheen. DEF 14A, filed 2026-04-15. Section “Director Compensation”. As printed: 434,985. View filing ↗
- Section 08, Alison C. Finger. DEF 14A, filed 2026-04-15. Section “Director Compensation”. As printed: 416,235. View filing ↗
- Section 08, Eduardo Rene Salas. DEF 14A, filed 2026-04-15. Section “Director Compensation”. As printed: 412,485. View filing ↗
- Section 08, Adam S. Grossman. DEF 14A, filed 2026-04-15. Section “Director Compensation”. As printed: 0. View filing ↗
- Section 02, Jerrold B. Grossman 2026-05-11. Form 4, filed 2026-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jerrold B. Grossman 2026-05-12. Form 4, filed 2026-05-14. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Jerrold B. Grossman 2026-05-27. Form 4, filed 2026-05-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Kohler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Paul Kohler 2026-07-16. Form 4, filed 2026-07-17. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 02, Kaitlin M. Kestenberg-Messina 2026-07-24. Form 4, filed 2026-07-28. Insider equity transaction reported since the proxy statement. View filing ↗
- Section 06, 2026 vote. Form 8-K, filed 2026-06-02. Item 5.07 · say-on-pay result. As reported: 95.43% (votes for as printed: 168,169,866 Shares). View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-06-04. Item 5.07 · say-on-pay result. As reported: 88.91% (votes for as printed: 161,456,980). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 495,000 + equity 1,049,916 + all other 0 = 1,544,916, summed across the director compensation table rows.
- Exelixis, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Exelixis, Inc.'s own proxy. As printed: 33,239,183. View filing ↗
- TG Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in TG Therapeutics, Inc.'s own proxy. As printed: 25,571,250. View filing ↗
- Halozyme Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-03-23. CEO total compensation as printed in Halozyme Therapeutics, Inc.'s own proxy. As printed: 23,166,223. View filing ↗
- Supernus Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-30. CEO total compensation as printed in Supernus Pharmaceuticals, Inc.'s own proxy. As printed: 15,501,557. View filing ↗
- Corcept Therapeutics Incorporated, Section 10b CEO total. DEF 14A, filed 2026-04-17. CEO total compensation as printed in Corcept Therapeutics Incorporated's own proxy. As printed: 15,303,551. View filing ↗
- Vericel Corporation, Section 10b CEO total. DEF 14A, filed 2026-03-19. CEO total compensation as printed in Vericel Corporation's own proxy. As printed: 11,156,368. View filing ↗
- Apellis Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-23. CEO total compensation as printed in Apellis Pharmaceuticals, Inc.'s own proxy. As printed: 10,957,451. View filing ↗
- Mirum Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-23. CEO total compensation as printed in Mirum Pharmaceuticals, Inc.'s own proxy. As printed: 10,441,224. View filing ↗
- ANI Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-09. CEO total compensation as printed in ANI Pharmaceuticals, Inc.'s own proxy. As printed: 10,278,620. View filing ↗
- Adma Biologics, Inc (subject), Section 10b CEO total. DEF 14A, filed 2026-04-15. CEO total compensation as printed in Adma Biologics, Inc's own proxy. As printed: 10,237,326. View filing ↗
- Intra-Cellular Therapies, Inc., Section 10b CEO total. DEF 14A, filed 2024-04-29. CEO total compensation as printed in Intra-Cellular Therapies, Inc.'s own proxy. As printed: 10,086,413. View filing ↗
- MannKind Corporation, Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in MannKind Corporation's own proxy. As printed: 9,300,485. View filing ↗
- Amicus Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-24. CEO total compensation as printed in Amicus Therapeutics, Inc.'s own proxy. As printed: 8,526,943. View filing ↗
- Amphastar Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-13. CEO total compensation as printed in Amphastar Pharmaceuticals, Inc.'s own proxy. As printed: 8,309,350. View filing ↗
- Acadia Pharmaceuticals Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Acadia Pharmaceuticals Inc.'s own proxy. As printed: 8,256,518. View filing ↗
- Alkermes plc, Section 10b CEO total. DEF 14A, filed 2026-04-06. CEO total compensation as printed in Alkermes plc's own proxy. As printed: 7,915,081. View filing ↗
- Harmony Biosciences Holdings, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-03. CEO total compensation as printed in Harmony Biosciences Holdings, Inc.'s own proxy. As printed: 7,899,535. View filing ↗
- Sarepta Therapeutics, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-24. CEO total compensation as printed in Sarepta Therapeutics, Inc.'s own proxy. As printed: 7,840,666. View filing ↗
- Catalyst Pharmaceuticals, Inc., Section 10b CEO total. DEF 14A, filed 2025-04-11. CEO total compensation as printed in Catalyst Pharmaceuticals, Inc.'s own proxy. As printed: 7,774,160. View filing ↗
- MiMedx Group, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in MiMedx Group, Inc.'s own proxy. As printed: 7,182,208. View filing ↗
- Evolus, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-29. CEO total compensation as printed in Evolus, Inc.'s own proxy. As printed: 6,412,214. View filing ↗
- Collegium Pharmaceutical, Inc., Section 10b CEO total. DEF 14A, filed 2026-04-07. CEO total compensation as printed in Collegium Pharmaceutical, Inc.'s own proxy. As printed: 1,715,846. View filing ↗
- Section 10a, TG Therapeutics, Inc. reciprocity. DEF 14A. TG Therapeutics, Inc. names Adma Biologics, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, MiMedx Group, Inc. reciprocity. DEF 14A. MiMedx Group, Inc. names Adma Biologics, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗
- Section 10a, MannKind Corporation reciprocity. DEF 14A. MannKind Corporation names Adma Biologics, Inc in its own disclosed peer group (read from its most recent proxy). View filing ↗